Skip to content

A CLINICAL TRIAL TO MEASURE IMPAIEMENT OF QUALITY OF LIFE OF VITILIGO PATIENTS USING VITILIGO IMPACT SCALE

A HOSPITAL-BASED VALIDATION OF VITILIGO IMPACT SCALE-22 IN A TERTIARY CARE HOSPITAL IN NORTH KARNATAKA - VIS-22

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011504
Enrollment
150
Registered
2018-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Vitiligo, superficial fungal infections, pityriasis rosea, scabies, seborrheic dermatitis, polymorphic light eruptions

Interventions

None listed

Sponsors

Shri B M Patil medical college hospital and research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients > 15years, suffering from any clinical type of vitiligo. 2)Patients with educational status of at least secondary level.

Exclusion criteria

Exclusion criteria: 1)Patients suffering from mental and cognitive impairments 2)Patients with other major skin disorders along with vitiligo like psoriasis, severe acne vulgaris, alopecia, melasma, which are likely to result in psychological morbidities. 3)Patients with associated hypothyroidism which may cause a depressed mood.

Design outcomes

Primary

MeasureTime frame
VIS-22 is a valid quality of life measurement scale among patients with vitiligoTimepoint: 1 year

Secondary

MeasureTime frame
VIS-22 is a valid, highly reliable and responsive scale to measure the impairment of QOL among vitiligo patients. The scale has better measurement properties compared to DLQI and Skindex-16 with vitiligo-specific questionsTimepoint: 1 year 6 months

Countries

India

Contacts

Public ContactAparna Palit

Shri B M Patil Medical College, Hospital and Research Center

apalit2011@gmail.com08352262770

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026